Which big bio­phar­ma com­pa­nies put R&D as their top pri­or­i­ty?

We love charts at End­points. They’re a great way to of­fer a snap­shot of the da­ta that high­light a dra­mat­ic com­par­i­son for read­ers. So we were de­light­ed when one of our read­ers came up with two new charts from last week’s spe­cial re­port on the top 15 R&D bud­gets in bio­phar­ma.

Aris An­ge­lis, re­search of­fi­cer and PhD can­di­date at the Lon­don School of Eco­nom­ics, first went to work com­par­ing how the com­pa­nies did at re­search spend­ing as a com­par­i­son to the per­cent­age of rev­enue spent on re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER